STRM MVs represent a novel, biologically derived delivery modality for advanced genetic therapies. As naturally occurring nanoparticles, MVs can be engineered to carry gene editing tools, RNA payloads, or therapeutic DNA, while minimizing some of the safety concerns associated with traditional viral vectors or synthetic delivery systems.
By leveraging their innate ability to home to bone marrow, STRM MVs are uniquely suited for delivering CRISPR components and replacement genes directly to hematopoietic stem cells. This targeted approach is designed to enable precise genome engineering while minimizing immune activation, supporting the development of safer, potentially curative therapies for genetic diseases at their source.
Designing in vivo cell and gene therapies without comprising payload, targeting, or the ability for repeat dosing because of delivery constraints.